US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Braveheart Bio

25.80

-1.6400-5.98%

Volume:465.51K

Turnover:12.06M

Market Cap:1.82B

PE:-22.71

High:27.95

Open:27.95

Low:24.98

Close:27.44

52wk High:32.00

52wk Low:24.61

Shares:70.65M

Float Shares:18.75M

Volume Ratio:4.58

T/O Rate:2.48%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.1360

EPS(LYR):-3.9270

ROE:--

ROA:--

PB:-23.25

PE(LYR):-6.57

Loading ...

Overview Company News Filings

Braveheart Bio Initiated at Buy by Stifel

Cantor Fitzgerald Initiates Braveheart Bio at Overweight With $40 Price Target

MT Newswires Live

Stifel Initiates Braveheart Bio at Buy With $45 Price Target

MT Newswires Live

Braveheart Bio, Inc. : TD Cowen Initiates Coverage with Buy Rating

THOMSON REUTERS

Braveheart Bio initiated with a Buy at Jefferies

Braveheart Bio initiated with a Buy at Goldman Sachs

U.S. Research Roundup-Adobe, Braveheart Bio, CACI International

TipRanks Analyst Salveen Richter Reiterates Buy on Braveheart Bio, Sets $48 12-Month Target on Strong HCM Opportunity for Lead Asset BHB-1893

Braveheart Bio Director Vineeta Agarwala Files Initial Beneficial Ownership Statement

Insiders Double Down on Braveheart Bio in Massive Confidence Play

OrbiMed Advisors Acquires 1.940.000 Braveheart Bio Common Shares Worth $ 34,92 Juta

Insiders Double Down as Major Investor Piles Into Braveheart Bio

Press Release: Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Top Midday Gainers

MT Newswires Live

Braveheart Bio Shares Rise After Market Debut

MT Newswires Live

Braveheart Bio opens at $30.20, IPO priced at $18 per share

Stock Track | Braveheart Bio Soars 67.78% in Debut After Upsized $383 Million IPO

U.S. Stocks on the MOVE-Ralph Lauren, Sempra, Parker-Hannifin, Lincoln International

Braveheart Bio indicated to open at $30, IPO priced at $18

Braveheart Bio Poised to Surge in New York Debut After Upsized $383 Million IPO

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/BRVE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BRVE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRVE\",,,,,undefined,":{"symbol":"BRVE","market":"US","secType":"STK","nameCN":"Braveheart Bio","latestPrice":25.8,"timestamp":1788198554487,"preClose":27.44,"halted":0,"volume":465508,"delay":0,"changeRate":-0.05976676384839652,"floatShares":18750000,"shares":70652838,"eps":-1.136,"marketStatus":"Trading","change":-1.64,"latestTime":"08-31 13:49:14 EDT","open":27.95,"high":27.95,"low":24.98,"amount":12058297.650192,"amplitude":0.108236,"askPrice":25.82,"askSize":100,"bidPrice":25.47,"bidSize":239,"shortable":3,"etf":0,"ttmEps":-1.136,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788206400000},"marketStatusCode":2,"adr":0,"listingDate":1785988800000,"exchange":"NASDAQ","adjPreClose":27.44,"preHourTrading":{"tag":"盘前","latestPrice":27.69,"preClose":27.44,"latestTime":"09:22 EDT","volume":78,"amount":2250.209988,"timestamp":1788182538713,"change":0.25,"changeRate":0.009111,"amplitude":0.000364},"postHourTrading":{"tag":"盘后","latestPrice":27.44,"preClose":27.44,"latestTime":"19:30 EDT","volume":1146,"amount":31446.24,"timestamp":1787959804964,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":4.576702},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRVE\",,,,,undefined,":{"symbol":"BRVE","floatShares":18750000,"roa":"--","roe":"--","lyrEps":-3.927011,"volumeRatio":4.576702,"shares":70652838,"dividePrice":0,"high":27.95,"amplitude":0.108236,"preClose":27.44,"low":24.98,"week52Low":24.61,"pbRate":"-23.25","week52High":32,"institutionHeld":0,"latestPrice":25.8,"committee":0.410029,"eps":-1.136,"divideRate":0,"volume":465508,"delay":0,"ttmEps":-1.136,"open":27.95,"prevYearClose":18,"prevWeekClose":27.44,"prevMonthClose":18,"prevQuarterClose":18,"fiveDayClose":27.5,"twentyDayClose":18,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BRVE\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BRVE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BRVE\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BRVE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BRVE","date":"2026-08-28","current":-22.711268,"percent":0.176471,"low":-23.993466,"twenty":-22.249941,"median":-22.006007,"eighty":-20.827928,"high":-12.297967,"avg":-20.978481,"sd":2.939385,"marketCap":1787746250},"quantilePoints":[{"date":"2026-08-07","current":-22.904964,"twenty":-19.277064,"median":-13.835213,"eighty":-12.912865,"marketCap":1837733965},{"date":"2026-08-14","current":-20.770344,"twenty":-22.55018,"median":-20.842324,"eighty":-16.302149,"marketCap":1666466982},{"date":"2026-08-21","current":-21.930028,"twenty":-22.591769,"median":-21.618113,"eighty":-20.309669,"marketCap":1759511923},{"date":"2026-08-28","current":-22.281932,"twenty":-22.249941,"median":-22.006007,"eighty":-20.827928,"marketCap":1787746250}],"updateTime":1788198554637},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BRVE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663072364","title":"Braveheart Bio Initiated at Buy by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2663072364","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663072364?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:36","pubTimestamp":1788172560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BRVE/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663224074","title":"Cantor Fitzgerald Initiates Braveheart Bio at Overweight With $40 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2663224074","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663224074?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:32","pubTimestamp":1788172345,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald Initiates Braveheart Bio at Overweight With $40 Price Target","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663718150","title":"Stifel Initiates Braveheart Bio at Buy With $45 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2663718150","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663718150?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:49","pubTimestamp":1788169786,"startTime":"0","endTime":"0","summary":"Stifel Initiates Braveheart Bio at Buy With $45 Price Target","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663079570","title":"Braveheart Bio, Inc. : TD Cowen Initiates Coverage with Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2663079570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663079570?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:38","pubTimestamp":1788169103,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S05T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663076785","title":"Braveheart Bio initiated with a Buy at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2663076785","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663076785?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:06","pubTimestamp":1788167163,"startTime":"0","endTime":"0","summary":"Jefferies initiated coverage of Braveheart Bio (BRVE) with a Buy rating and $48 price target The two Phase II datasets from the company’s China par...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/braveheart-bio-initiated-with-a-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/braveheart-bio-initiated-with-a-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BRVE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663341075","title":"Braveheart Bio initiated with a Buy at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2663341075","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663341075?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:35","pubTimestamp":1788165310,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Salveen Richter initiated coverage of Braveheart Bio (BRVE) with a Buy rating and $48 price target Braveheart is a clinical-s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/braveheart-bio-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/braveheart-bio-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0061475181.USD","LU1868836914.USD","LU0742534661.SGD","LU2471134523.USD","IE00B19Z3B42.SGD","LU2471134796.USD","IE0004086264.USD","LU0106831901.USD","LU2237443978.SGD","LU2471134879.HKD","BK4552","LU0251142724.SGD","LU0048573561.USD","IE00B19Z3581.USD","LU0096364046.USD","LU1668664300.SGD","LU0345770993.USD","LU2237443549.SGD","LU2237443895.HKD","BK4007","LU1868836591.USD","IE00BSNM7G36.USD","LU1868836757.USD","LU2471134952.CNY","LU2237443382.USD","BK4533","LU1894683348.USD","LU1894683264.USD","LU2750360641.GBP","LU0345770308.USD","LU2265009873.SGD","LU2750360997.AUD","LU2237438978.USD","LU1868837136.USD","BK4588","GSX","LU1804176565.USD","LU2896262040.SGD","LU1144417596.USD","LU0868494708.USD","LU0210536198.USD","BK4504","BRVE","BK4516","BK4127","IE0004091025.USD","IE0034235188.USD","LU1791807156.HKD","IE00BFXG1179.USD","LU0942090050.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663020059","title":"U.S. Research Roundup-Adobe, Braveheart Bio, CACI International","url":"https://stock-news.laohu8.com/highlight/detail?id=2663020059","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663020059?lang=en_us&edition=fundamental","pubTime":"2026-08-31 15:24","pubTimestamp":1788161046,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Adobe, Braveheart Bio, CACI InternationalAug 31 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adob","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL4N44S0J8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TROW","BW","SRE","ETR","MADE","EIX","CIEN","CRM","DE","AIRJ","RKLB","SBRA","ICE","BPOP","FIVN","HQY","WSPC","ANF","PYPL","PCG","MDB","PUI","RVMD","CACI","SRET","RBRK","IBM","ATTO","ADSK","RDW","BRVE","BCDF","SCTX","BRCC","HONA","ADBE","FSPC","OHI","PATH","AFRM","LUNR","ASST","VEGI","DLTR","ATI","BAC","KALU","PTGX","FXU","BURL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663027370","title":"TipRanks Analyst Salveen Richter Reiterates Buy on Braveheart Bio, Sets $48 12-Month Target on Strong HCM Opportunity for Lead Asset BHB-1893","url":"https://stock-news.laohu8.com/highlight/detail?id=2663027370","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663027370?lang=en_us&edition=fundamental","pubTime":"2026-08-31 14:16","pubTimestamp":1788156960,"startTime":"0","endTime":"0","summary":"Braveheart Bio, Inc. (BRVE) has received a new Buy rating, initiated by Goldman Sachs analyst, Salveen Richter. Salveen Richter has given his Buy r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tipranks-analyst-salveen-richter-reiterates-buy-on-braveheart-bio-sets-48-12-month-target-on-strong-hcm-opportunity-for-lead-asset-bhb-1893-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tipranks-analyst-salveen-richter-reiterates-buy-on-braveheart-bio-sets-48-12-month-target-on-strong-hcm-opportunity-for-lead-asset-bhb-1893-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0004091025.USD","DBB","IE0002270589.USD","BK4550","LU2471134952.CNY","LU2237443622.USD","BK4211","LU2237438978.USD","LU2471134796.USD","LU1868837136.USD","LU0061475181.USD","LU0868494708.USD","GSX","LU1791807156.HKD","LU2750360997.AUD","BK4504","BK4533","BK4585","LU0106831901.USD","LU0942090050.USD","LU1868836591.USD","LU2750360641.GBP","LU2237443895.HKD","LU0345770308.USD","IE00BFXG1179.USD","LU0096364046.USD","LU1668664300.SGD","BRVE","IE00B19Z3B42.SGD","LU2265009873.SGD","LU2896262040.SGD","LU2471134879.HKD","LU0251142724.SGD","LU0868494617.USD","IE0004086264.USD","LU1894683348.USD","LU1868836757.USD","IE0034235188.USD","BK4552","BK4127","LU2237443382.USD","LU1804176565.USD","LU1868837300.USD","BK4588","LU0251131958.USD","BK4516","LU0210536198.USD","LU1868836914.USD","BHB","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659243121","title":"Braveheart Bio Director Vineeta Agarwala Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2659243121","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659243121?lang=en_us&edition=fundamental","pubTime":"2026-08-15 05:05","pubTimestamp":1786741522,"startTime":"0","endTime":"0","summary":"Braveheart Bio director Vineeta Agarwala files initial beneficial ownership statementDirector Vineeta Agarwala filed an initial Form 3 for Braveheart Bio, reporting indirect ownership of 10,232,420 co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL4ChQML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658947790","title":"Insiders Double Down on Braveheart Bio in Massive Confidence Play","url":"https://stock-news.laohu8.com/highlight/detail?id=2658947790","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658947790?lang=en_us&edition=fundamental","pubTime":"2026-08-12 10:01","pubTimestamp":1786500109,"startTime":"0","endTime":"0","summary":"New insider activity at Braveheart Bio, Inc. ( ($BRVE) ) has taken place on August 11, 2026. Braveheart Bio, Inc. has attracted substantial insider...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insiders-double-down-on-braveheart-bio-in-massive-confidence-play-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insiders-double-down-on-braveheart-bio-in-massive-confidence-play-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658494615","title":"OrbiMed Advisors Acquires 1.940.000 Braveheart Bio Common Shares Worth $ 34,92 Juta","url":"https://stock-news.laohu8.com/highlight/detail?id=2658494615","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658494615?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:28","pubTimestamp":1786483716,"startTime":"0","endTime":"0","summary":"OrbiMed Advisors acquires 1.940.000 Braveheart Bio common shares worth $ 34,92 jutaBraveheart Bio melaporkan OrbiMed Advisors meningkatkan kepemilikan tidak langsung menjadi 11.901.826 saham biasa.Pos","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL8hq9sF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"OrbiMed Advisors Acquires 1.940.000 Braveheart Bio Common Shares Worth $ 34,92 Juta","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657622953","title":"Insiders Double Down as Major Investor Piles Into Braveheart Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2657622953","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657622953?lang=en_us&edition=fundamental","pubTime":"2026-08-08 10:02","pubTimestamp":1786154530,"startTime":"0","endTime":"0","summary":"New insider activity at Braveheart Bio, Inc. ( ($BRVE) ) has taken place on August 7, 2026. Braveheart Bio, Inc. has seen a wave of insider and maj...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insiders-double-down-as-major-investor-piles-into-braveheart-bio-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insiders-double-down-as-major-investor-piles-into-braveheart-bio-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657268036","title":"Press Release: Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2657268036","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657268036?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:05","pubTimestamp":1786133100,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","BK4531","IPOS","LU0124676726.USD","LU0289739343.SGD","LU0472753341.HKD","BK4149","BK4588","LU0689626769.HKD","LU0154245673.USD","LU0203347892.USD","LU0289961442.SGD","HCM","LU0154245756.USD","CMI","IE000M9KFDE8.USD","BK4533","BK4007","LU0057025933.USD","LU0511384066.AUD","BK4567","MADE","BK4585","BRVE","LU0069063385.USD","LU0203345920.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651922","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651922","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651922?lang=en_us&edition=fundamental","pubTime":"2026-08-07 01:58","pubTimestamp":1786039111,"startTime":"0","endTime":"0","summary":"ClearOne's  majority stockholder, First Finance, has provided written consent approving the issuance of 12.5 million new common shares to Vivani Medical, a condition required to close its planned merger with Vivani unit Cortigen, the company said in a regulatory filing.Shares of ClearOne soared 157% amid a surge in intraday trading volume to over 59.7 million from a daily average of about 3.23 million.Braveheart Bio's  unveiled an upsized initial public offering of 21.25 million common shares late Wednesday.Shares surged 66% as intraday trading volume jumped to over 1.74 million.Motorola Solutions  delivered a better-than-expected Q2, driven by continued outperformance from Silvus Technologies in defense markets and a surprise return to growth in its Land Mobile Radio business, Morgan Stanley said in a Thursday research note.Shares jumped 8.2%, with intraday trading volume rising to more than 1.06 million from the stock's daily average of about 1.13 million.Price: 9.37, Change: +5.61, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1992135472.HKD","LU2473716301.USD","LU2089284900.SGD","LU1244550221.USD","LU2322448791.USD","LU1989772840.SGD","LU0234570918.USD","LU1162221912.USD","LU0106261372.USD","BK7031","MSI","IAI","BK4127","BRVE","LU1791710400.SGD","LU1732800096.USD","LU0210528500.USD","LU2271345857.HKD","CLRO","LU2272731600.USD","LU0107464264.USD","IE00BZ1G4Q59.USD","BK4504","LU1548497426.USD","LU2487616109.SGD","LU2028103732.USD","LU2125909916.SGD","LU2264538146.SGD","LU0557290698.USD","LU1074936037.SGD","KBWB","LU2111349929.HKD","LU2106854487.HKD","LU2125909759.SGD","LU1992135399.USD","LU2133065610.SGD","LU0320765646.SGD","LU0354030438.USD","LU1923622291.USD","LU2065171402.SGD","LU1720051108.HKD","LU0795875086.SGD","EYES","LU0314104364.USD","LU0823417737.USD","LU0882574139.USD","MSI.AU","BK4534","LU2272731865.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657659460","title":"Braveheart Bio Shares Rise After Market Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2657659460","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657659460?lang=en_us&edition=fundamental","pubTime":"2026-08-07 01:25","pubTimestamp":1786037119,"startTime":"0","endTime":"0","summary":"Braveheart Bio  shares rose 69.8% in Thursday trading after the company announced an upsized initial public offering of 21.25 million common shares late Wednesday.The stock opened for trading Thursday at $30.20, compared with its public offering price of $18 per share.The offering is expected to close Friday, subject to customary closing conditions.Price: 30.53, Change: +12.53, Percent Change: +69.58","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656750","title":"Braveheart Bio opens at $30.20, IPO priced at $18 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656750","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657656750?lang=en_us&edition=fundamental","pubTime":"2026-08-07 00:55","pubTimestamp":1786035323,"startTime":"0","endTime":"0","summary":"Braveheart Bio (BRVE) – a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy and othe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/braveheart-bio-opens-at-30-20-ipo-priced-at-18-per-share-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/braveheart-bio-opens-at-30-20-ipo-priced-at-18-per-share-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRHC","REDS","IPOS","BK4127","BRVE","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150536472","title":"Stock Track | Braveheart Bio Soars 67.78% in Debut After Upsized $383 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1150536472","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150536472?lang=en_us&edition=fundamental","pubTime":"2026-08-07 00:52","pubTimestamp":1786035174,"startTime":"0","endTime":"0","summary":"Shares of Braveheart Bio Inc. (BRVE) soared 67.78% during intraday trading on Thursday, marking a stellar debut on the Nasdaq Global Market.The surge comes after the clinical-stage biopharmaceutical...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657703655","title":"U.S. Stocks on the MOVE-Ralph Lauren, Sempra, Parker-Hannifin, Lincoln International","url":"https://stock-news.laohu8.com/highlight/detail?id=2657703655","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657703655?lang=en_us&edition=fundamental","pubTime":"2026-08-07 00:22","pubTimestamp":1786033341,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Ralph Lauren, Sempra, Parker-Hannifin, Lincoln InternationalAugust 6 (Reuters)-Wall Street's benchmark S&P 500 struggled for direction in choppy trading on Thursday as inv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL6N44314S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELF","VTRS","HONA","LCLN","MRNA","PTON","SNDK","PH","OSCR","RXO","FOUR","FRT","BLLN","RL","PZZA","DDOG","MAC","APP","WDC","KVUE","UWMC","KDP","USFD","INSM","CELH","FISV","HWM","IOVA","RDVT","MTSI","CHYM","RCBC","SITM","SPCX","U","LEU","CEG","GBFH","SMR","VCTR","FIG","PAYC","LNG","EPAM","PRMB","BRVE","SRE","FLNC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657555236","title":"Braveheart Bio indicated to open at $30, IPO priced at $18","url":"https://stock-news.laohu8.com/highlight/detail?id=2657555236","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657555236?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:50","pubTimestamp":1786031427,"startTime":"0","endTime":"0","summary":"Braveheart Bio (BRVE) priced 21.25M shares at $18.00. The deal size was increased to 21.25M shares of common stock from 18.75M shares and priced ab...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/braveheart-bio-indicated-to-open-at-30-ipo-priced-at-18-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/braveheart-bio-indicated-to-open-at-30-ipo-priced-at-18-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KCE","REDS","BRVE","IPOS","BK4127","FRHC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657865868","title":"Braveheart Bio Poised to Surge in New York Debut After Upsized $383 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2657865868","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657865868?lang=en_us&edition=fundamental","pubTime":"2026-08-06 22:49","pubTimestamp":1786027798,"startTime":"0","endTime":"0","summary":"BUZZ-Braveheart Bio poised to surge in New York debut after upsized $383 million IPO** Drug developer Braveheart BioBRVE.Oon track to open above offer price in Nasdaq debut after upsized $382.5 million U.S. IPO** Stock recently indicated to open at $25 apiece vs $18 offer price** San Francisco, California-based BRVE sold ~21.3 million shares inupsized IPOat $18 apiece** BRVE, which is developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases, had initially marketed 18.75 million shares priced between $15 and $17** Goldman Sachs, Jefferies, TD Cowen, Stifel and Cantor acted as joint book-running managers for offering","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL6N44311L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SF","IE0034235188.USD","IE00BSNM7G36.USD","IE0002270589.USD","LU1791807156.HKD","LU0061475181.USD","LU2237443382.USD","BRVE","LU0251142724.SGD","GSX","LU0251131958.USD","LU1868837300.USD","LU0742534661.SGD","IE0004086264.USD","LU0868494617.USD","LU0868494708.USD","LU1804176565.USD","LU2471134796.USD","LU2750360641.GBP","LU1868836914.USD","BK4504","LU2237443465.HKD","LU2471134523.USD","LU1868836591.USD","LU0096364046.USD","LU1894683264.USD","LU2237438978.USD","LU0106831901.USD","LU2237443978.SGD","BK4550","LU1894683348.USD","IE0004091025.USD","LU2265009873.SGD","LU2471134952.CNY","LU2237443622.USD","BK4533","LU2237443895.HKD","LU1668664300.SGD","BK4552","IE00BFXG1179.USD","LU0942090050.USD","LU0048573561.USD","IE00B19Z3B42.SGD","BK4127","LU2471134879.HKD","LU2237443549.SGD","LU0345770308.USD","LU0345770993.USD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":25,"code":"91000000","status":"200"}]}}